Clincosm LogoSign in Get a demo

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Sponsor
University Health Network, Toronto (Other)
Overall Status
Recruiting
CT.gov ID
NCT05403177
Collaborator
Princess Margaret Hospital, Canada (Other), Ontario Institute for Cancer Research (Other), Terry Fox Research Institute (Other)
500
Enrollment
1
Location
51.6
Anticipated Duration (Months)
9.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
    Anticipated Study Start Date :
    Jun 13, 2022
    Anticipated Primary Completion Date :
    Oct 1, 2026
    Anticipated Study Completion Date :
    Oct 1, 2026

    Arms and Interventions

    Arm Intervention/Treatment
    MOHCCN-O

    Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data [5 years]

    Secondary Outcome Measures

    1. Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases [5 years]

    2. Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions [5 years]

      Health technology assessment tools will be used to evaluate the real-world value of precision medicine

    3. Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine [5 years]

      Health technology assessment tools will be used to evaluate the real-world value of precision medicine

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Patients with histological and cytological confirmation of blood or solid tumor malignancies.

    2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

    • existing data that satisfies the minimal requirements of a gold standard case, AND/OR

    • previously collected and sufficient biospecimens (tumor and/or blood samples) for whole-genome and transcriptome sequencing and immunophenotype characterization, AND/OR

    • new blood collection and/or tumor biopsy

    1. Agrees to share anonymized clinical and genomic data.
    Exclusion Criteria:

    None.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Princess Margaret Cancer Centre Toronto Ontario Canada M5G2M9

    Sponsors and Collaborators

    • University Health Network, Toronto
    • Princess Margaret Hospital, Canada
    • Ontario Institute for Cancer Research
    • Terry Fox Research Institute

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Health Network, Toronto
    ClinicalTrials.gov Identifier:
    NCT05403177
    Other Study ID Numbers:
    • MOHCCN-O
    First Posted:
    Jun 3, 2022
    Last Update Posted:
    Jun 8, 2022
    Last Verified:
    Jun 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Kidney Neoplasms
    Pancreatic Neoplasms
    Ovarian Neoplasms

    Study Results

    No Results Posted as of Jun 8, 2022